You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here

Reach

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

    Status Completed
    Related Conditions
    Rheumatoid Arthritis

Enrollment Details

Phases: 

  • 1
  • 2
  • 3
  • 4
Study Type:  Observational

This is a type IV phase trial.

Protocol ID
PMOS-CANA-04-01

Brief summary

Top

The REACH study is conducted to describe the clinical effectiveness of adalimumab (HUMIRA) in subjects with moderately to severely active Rheumatoid Arthritis (RA) that are receiving anti-rheumatic treatments including adalimumab.

Participant Attributes :
  • Male and Female
  • Ages 18 Years and older

Canada: 79

0
Bowmanville, ON
1
Burnaby, BC
2
Calgary, AB
3
Calgary, AB
4
Calgary, AB
5
Calgary, AB
6
Calgary, AB
7
Toronto, ON
8
Edmonton, AB
9
Edmonton, AB
10
Fredericton, NB
11
Guelph, ON
12
Kamloops, BC
13
Kelowna,
14
Kitchener,
15
Laval,
16
Lunenburg,
17
Montreal,
18
Montreal,
19
Nanaimo, BC
20
Ottawa, ON
21
North Vancouver, BC
22
Ottawa, ON
23
Owen Sound, ON
24
,
25
Prince George,
26
Toronto,
27
Sherbrooke,
28
Sherbrooke,
29
St. Catharines,
30
St. John's,
31
Toronto,
32
Toronto, ON
33
Toronto, ON
34
Toronto, ON
35
Vancouver, BC
36
Windsor, ON
37
Winnipeg, MB
38
Brampton, ON
39
Brampton, ON
40
Brampton, ON
41
Cranbrook, BC
42
Edmonton, AB
43
Edmonton, AB
44
Edmonton, AB
45
Fredericton, NB
46
Hamilton, ON
47
Hamilton, ON
48
Hamilton, ON
49
Hamilton, ON
50
Kamloops, BC
51
Levis, QC
52
Mississauga, ON
53
Mississauga, ON
54
Montreal, QC
55
Montreal, QC
56
Montreal, QC
57
Montreal, QC
58
Westmount, QC
59
Montreal, QC
60
Newmarket, ON
61
Toronto, ON
62
Ottawa, ON
63
Ottawa, ON
64
Montreal, QC
65
Penticton, BC
66
Penticton, BC
67
Rimouski, QC
68
Saint-Eustache, QC
69
St. John's, NL
70
Toronto, ON
71
Toronto, ON
72
Toronto, ON
73
Trois-Rivières, QC
74
Vancouver, BC
75
Vancouver, BC
76
Victoria, BC
77
Victoria, BC
78
Winnipeg, MB
Would you like to know more about this trial?

Study Design

  • The general design that describes the strategy for identifying and following up with participants during observational studies.
    ?

    Observational Model

    Cohort

  • The relationship between the observation period and the time of patient enrollment. Time perspective can be prospective: looking forward using periodic observations usually collected following patient enrollment, or retrospective: looking back using observations usually collected prior to patient selection and enrollment.
    ?

    Time Perspective

    Prospective

    • Patient is eligible to take part in the registry as per the product monograph.
    • Patients that are naïve to adalimumab therapy / or patients that have been receiving adalimumab therapy for less than 4 months.
    • Patient has moderately to severely active RA.
    • Patient who has had an inadequate response to one or more Disease Modifying Anti-Rheumatic Drugs (DMARDs).
    • Patient received provincial or private (insurance companies) approval for adalimumab.
    • Patient is able to give written informed consent and to understand the survey requirements.
    • Patient to whom a traditional DMARD had never been tried.
    • Patient with a known hypersensitivity to adalimumab, or any of its components.
    • Patient is receiving free adalimumab as part of a compassionate program or an early access drug distribution program.
    • Patient with clinically significant concurrent medical or psychiatric disorders that may influence survey outcomes.
    • Patient with any condition that would prevent participation in the survey and completion of the survey procedures including language limitation or possibility that the patient will not be available for a period of time (> 12 months) while being enrolled in the survey.

More on this trial

Clinical Trials.gov